Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Enterprise Value of -$404.3 million for Q4 2025, down 46.89% year-over-year from -$761.2 million in Q4 2024, and little changed quarter-over-quarter from -$402.6 million in Q3 2025.
Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$404.3 million for Q4 2025.
- In Q4 2025, Enterprise Value fell 46.89% year-over-year to -$404.3 million; the TTM figure through Dec 2025 stood at -$404.3 million (down 46.89% YoY), while the FY2025 annual figure was -$404.3 million, down 46.89% from the prior year.
- Enterprise Value for Q4 2025 stood at -$404.3 million, roughly flat from -$402.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$52.9 million in Q1 2023, with the low at -$404.3 million in Q4 2025.
- The 5-year median for Enterprise Value is -$191.2 million (2021), against an average of -$214.0 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 66.22% in 2023, then sank 612.8% in 2024.
- Dianthus Therapeutics' Enterprise Value stood at -$176.9 million in 2021, then jumped by 57.33% to -$75.5 million in 2022, then plunged by 130.12% to -$173.7 million in 2023, then plunged by 58.44% to -$275.2 million in 2024, then sank by 46.89% to -$404.3 million in 2025.
- Business Quant data shows DNTH's Enterprise Value at -$404.3 million in Q4 2025, -$402.6 million in Q3 2025, and -$257.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | -404.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -404.30 Mn |
| Sep 30, 2025 | -402.61 Mn |
| Jun 30, 2025 | -257.39 Mn |
| Mar 31, 2025 | -263.23 Mn |
| Dec 31, 2024 | -275.24 Mn |
| Sep 30, 2024 | -281.12 Mn |
| Jun 30, 2024 | -360.71 Mn |
| Mar 31, 2024 | -377.04 Mn |
| Dec 31, 2023 | -173.72 Mn |
| Sep 30, 2023 | -189.87 Mn |
| Jun 30, 2023 | -55.24 Mn |
| Mar 31, 2023 | -52.90 Mn |
| Dec 31, 2022 | -75.49 Mn |
| Sep 30, 2022 | -106.14 Mn |
| Jun 30, 2022 | -139.43 Mn |
| Mar 31, 2022 | -156.60 Mn |
| Dec 31, 2021 | -176.93 Mn |
| Sep 30, 2021 | -192.62 Mn |
| Jun 30, 2021 | -207.81 Mn |
| Mar 31, 2021 | -132.29 Mn |